Shattuck Labs, Inc. (STTK)
About Shattuck Labs, Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.0M
- Net income
- -$48.8M
- Total assets
- $91.0M
- Market cap
- $351.2M
- Operating margin
- -5150.8%
- Net margin
- -4880.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.0M
- Operating expenses
- $52.5M
- Operating income
- -$51.5M
- Income tax
- $0
- Net income
- -$48.8M
- EPS (basic)
- $-0.70
- EPS (diluted)
- $-0.70
Balance sheet
- Total assets
- $91.0M
- Current assets
- $82.5M
- Total liabilities
- $8.6M
- Current liabilities
- $7.1M
- Shareholders’ equity
- $82.4M
Cash flow
- Operating cash flow
- -$39.9M
- Investing cash flow
- -$7.9M
- Financing cash flow
- $44.6M
- Net cash flow
- -$3.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $351.2M
- EPS (diluted)
- $-0.7
- Shares outstanding
- 47.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 9, 2020
Shattuck Labs, Inc. (STTK) Stock Price
- Reported a net loss of $48.8M in FY2025.
- Revenue declined 97% from FY2021 to FY2025.
- Trading 6% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Shattuck Labs, Inc..
Write a review
News about Shattuck Labs, Inc.
News & sentiment via Polygon.io
Shattuck Labs, Inc.: frequently asked questions
Is Shattuck Labs, Inc. an American company?
Shattuck Labs, Inc. is a US-based company headquartered in Austin, Texas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Shattuck Labs, Inc. headquartered?
Shattuck Labs, Inc. is headquartered in Austin, Texas, United States.
Is Shattuck Labs, Inc. publicly traded?
Yes — Shattuck Labs, Inc. is a publicly traded company. Its stock trades under the ticker symbol STTK on the NASDAQ.
What does Shattuck Labs, Inc. do?
Shattuck Labs, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
